• Hautarzt · Dec 1979

    [Immunotherapeutic possibilities for treatment of malignant melanomas].

    • E M Kokoschka.
    • Hautarzt. 1979 Dec 1; 30 (12): 656-61.

    AbstractPrinciples, possibilities and limits of an immunotherapy of malignant melanoma are discussed. On account of the results of immunological investigations in melanoma patients and in animal models the immunogenicity of melanoma cells and the stage dependent immune reactivity of tumor bears seem to be certain. These facts have been the rational basis for the evaluation of an immunotherapy in malignant melanoma. Netherless these therapy trials are still in the state of clinical testing. Controlled long term studies of immunotherapy schedules under observation of the immune profile of the patients in vivo and in vitro are necessary in order to determine the place of immunotherapy within the range of oncological therapeutic possibilities.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!

We guarantee your privacy. Your email address will not be shared.